Editas Medicine Inc logo

Editas Medicine Inc

$ 17.34 -1.12 (-6.07%) 04:00 PM EST
P/E:
At Loss
P/B:
2.66
Market Cap:
$ 1.19B
Enterprise V:
$ 836.59M
Volume:
1.94M
Avg Vol (2M):
1.89M
Also Trade In:
Volume:
1.94M
Market Cap $:
1.19B
PE Ratio:
At Loss
Avg Vol (2-Month):
1.89M
Enterprise Value $:
836.59M
PB Ratio:
2.66
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download Tutorials

Business Description

Editas Medicine Inc
NAICS : 325412 SIC : 2834
11 Hurley Street, Cambridge, MA, USA, 02141
Description
Editas Medicine Inc is a gene-editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company's only operating segment is developing and commercializing genome editing technology.
Name Current Vs Industry Vs History
Cash-To-Debt 22.34
Equity-to-Asset 0.8
Debt-to-Equity 0.04
Debt-to-EBITDA -0.11
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 4.16
Distress
Grey
Safe
Beneish M-Score 0.86
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 54.41
9-Day RSI 58.5
14-Day RSI 59.8
6-1 Month Momentum % -9.97
12-1 Month Momentum % -76.08

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 12.67
Quick Ratio 12.67
Cash Ratio 12.43
Days Sales Outstanding 6.73

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -12

Financials (Next Earnings Date:2022-11-08 Est.)

EDIT's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:EDIT

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 31.799
EPS (TTM) ($) -2.7
Beta 1.99
Volatility % 91.11
14-Day RSI 59.8
14-Day ATR ($) 1.318169
20-Day SMA ($) 17.4875
12-1 Month Momentum % -76.08
52-Week Range ($) 9.59 - 73.025
Shares Outstanding (Mil) 68.74

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Editas Medicine Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More